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INTRODUCTION 
 
 Pneumonia  is  the  second  most  common  nosocomial  infection  
diagnosed  in  intensive  care  units .  Pneumonia  is  defined  as  nosocomial  
when  it  occurs  more  than  48  hours  after  the  patient’s  admission  to  
the  hospital  and  when  it  was not  in  incubation  at  the  time  of  
hospitalization.  Ventilator  Associated  Pneumonia (VAP)  is  a  subset  of  
pneumonia  and  the  term  refers  to  nosocomial  pneumonia  in  a  patient  
on  mechanical  ventilator  for  greater  than  or  equal  to  48  hours. 
 
 Ventilator  associated  pneumonia   poses  a  major  threat  to  patients  
admitted  in  intensive  care  units  and  receiving  mechanical  ventilation.  
86 %  of  nosocomial  pneumonias  are  associated  with  mechanical 
ventilation  and  are  termed  ventilator  associated  pneumonia. 
 
 Endotracheal  intubation  is  the  most  important  risk  factor  for  
developing  VAP.  Critically  ill  patients  who  are  intubated  for  more  
than  24  hours  were  found  to  be  at  6  to  21  times  higher  risk  of  
developing  VAP  and  those  intubated  for  less  than  24  hours  are  at  3  
times  the  risk  for  developing  VAP,  compared  to  non- intubated  
patients.   
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 Other  risk  factors  for  VAP  include  depressed  level  of  
consciousness,  gastric  distension  and  presence  of  gastric  or  small  
intestinal  tubes,  trauma,  COPD.  VAP  is  reported  to  occur  at  rates  of  
10  to  35  cases  per 1000  ventilator  days,  depending  on  the  clinical  
situation.  Incidence  of  VAP  increases  with  the  duration  of  mechanical  
ventilation.   
 
 VAP  is  most  commonly  due  to  gram  negative  organisms.  
Estimates  of  attributable  mortality  are  variable,  but  increased  duration  
of  ventilation  is  a  consistent  finding,  along  with  corresponding  
increase  in  hospital  days  and  cost. 
 
 A  major  component  of  the  problem  is  the  ineffectiveness  of  
therapy  once  VAP  is  diagnosed.  Brun- Buisson  et  al  have  
demonstrated  failure  rates  of  49  to  62%  despite  the  use  of   standard  
antibiotic  combinations.  Given  the  burden  of  VAP,  both  physical  and  
financial, the   difficulties  in  treatment,  prevention  strategies  would  
appear  to  be  of  paramount  importance. 
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 In  this  study  the  incidence,   risk  factors   and  outcome  of  VAP  
were  analysed  along  with  bacterial  pathogens  causing  VAP  and  
significance  of  Clinical  Pulmonary  Infection  Score (CPIS). 
  
Aims & Objectives 
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AIMS  AND OBJECTIVES 
 
1) To  study  the  incidence  and  aetiology  of  VAP. 
2) To  study  the  risk  factors  involved  in  causation  of  VAP. 
3) To  identify  the  various  pathogens  causing  VAP. 
4) To  identify  the  significance  of  Clinical  Pulmonary  Infection  Score  
as  a  prognostic  indicator.  
  
Review of Literature 
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REVIEW OF LITERATURE 
 
 VAP is an important intensive care unit acquired pulmonary infection 
in mechanically ventilated patients. 
 VAP is the second most common nosocomial infection and remains a 
major cause of hospital morbidity and mortality. 
 Pneumonia is infection of the lung parenchyma. 
 VAP is defined as pneumonia that occurs 48 hours or more after 
endotracheal intubation or tracheostomy caused by infectious 
organisms not present or incubating at the time mechanical ventilation 
was started.(1) 
 Prevalence varies between 6 and 52 cases per 100 patients.(2) 
 
VAP is of two types: 
i) Early Onset VAP - VAP which occurs within first 4 days of 
ventilation; commonly caused by antibiotic sensitive organisms. 
ii) Late Onset VAP – VAP which occurs after four days of 
mechanical ventilation more likely attributed to drug resistant 
organisms.(3) 
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Pathogenesis: 
- Pneumonia occurs from proliferation of microbial pathogens at the 
alveolar level and host’s response to those pathogens. 
- Micro organisms gain access to the lower respiratory tract mainly by 
aspiration from the oropharynx. 
- The pathogens gain entry by inhalation route as contaminated 
droplets, by hematogenous spread or by continuous extension from an 
infected pleura or mediastinum. 
- The mechanical factors in the host critical in the defense against 
pathogens include 
o hair and turbinates of the nares which capture large inhaled 
particles before reaching the lower respiratory tract. 
o branching architecture of tracheobronchial tree which traps 
microbes. 
o mucociliary clearance 
o local antibacterial factors 
o Gag reflex and cough reflex 
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- When these mechanical barriers are overcome or when the size of 
microbe is very small they are inhaled to the alveolar level. 
- Hence the factors involved in the genesis of respiratory infection include 
immunodeficiency in the host; inoculation of microbes into the lower 
respiratory tract and a highly virulent organism. 
- The concomitant factors in ICU patients include immunodeficiency 
related to diabetes mellitus or glucocorticoid therapy.(4) 
- Malnutrition, contaminated equipment, cross infection from other 
patients are other additional risk factors. 
- The most obvious risk factor for VAP is the presence of endotracheal 
tube that bypasses the normal mechanical factors preventing aspiration.(5) 
- While endotracheal tube prevents large volume aspiration, 
microaspiration is exacerbated by secretions pooling around the cuff. 
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- The endotracheal tube and concomitant need for suctioning damages the 
tracheal mucosa promoting its colonization by pathogens. 
- The pathogenic bacteria forms a glycocalyx biofilm on the tube’s surface 
that is resistant to both antibiotics and host defense mechanism. 
- In critically ill patients the normal flora in oropharynx is replaced by 
pathogenic microbes and almost all intubated patients experience 
microaspiration and are transiently colonized with these pathogens. 
- But only one third of colonized patients develop VAP. 
- When the barriers are overcome or when the pathogens are small enough 
to be inhaled they reach the alveolar levels, where they are efficiently 
cleared and killed by the resident alveolar macrophages. 
- The alveolar macrophages are aided by the epithelial cells like surfactant 
proteins A and D which have opsonizing properties and antibacterial and 
antiviral activity. 
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- The pathogens even if they are not killed but once engulfed are cleared 
by mucociliary elevator or lymphatics and are no longer an infectious 
challenge. 
- Once the capacity of alveolar macrophages to ingest or kill the microbes 
is exceeded clinical pneumonia manifests. 
- Also there is initiation of inflammatory response by the alveolar 
macrophages. 
- It is the host inflammatory response that produces the clinical syndrome 
of pneumonia rather than proliferation of microbes. 
- Fever is due to release of inflammatory mediators like interleukin 1 and 
tumor necrosis factor. 
- Peripheral leukocytosis and purulent secretions are due to interleukin 8 
and granulocyte colony stimulating factor which causes release of 
neutrophils and their attraction to the lungs. 
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- Inflammatory mediators cause recruitment of new neutrophils and 
creates alveolar capillary leak similar to that seen in adult respiratory 
distress syndrome, but the leak is initially localized in pneumonia. 
- Hemoptysis occurs when erythrocytes cross the alveolar – capillary 
membrane. 
- The capillary leak is responsible for the radiographic infiltrate and rales 
on auscultation. 
- Hypoxemia is due to alveolar filling. 
- Severe hypoxemia is due to interference of hypoxemic vasoconstriction 
by bacterial pathogens  that  normally  occurs  with fluid  filled   alveoli. 
- Respiratory alkalosis is due to increased respiratory drive caused by 
systemic inflammatory response. 
- Dyspnea is due to reduced compliance by capillary leak, hypoxemia, 
enhanced respiratory drive, secretions and infection related 
bronchospasm. 
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- If the changes in lung mechanics are severe enough due to decrease in 
lung volume and compliance, respiratory failure and death occurs due to 
intrapulmonary shunting of blood. 
- There is a series of pathologic changes in the evolution of classic 
pneumonia. 
 
1) Edema is the initial phase due to proteinaceous exudate and bacteria in 
the alveoli. 
2) Red hepatization phase is due to erythrocytes in the cellular intra 
alveolar exudate. 
3) Gray hepatization phase - no new erythrocytes extravasate and existing 
ones are being lysed and degraded. 
- There is predominance of neutrophils with fibrin deposition and no 
bacteria. 
- This phase indicates successful containment of infection and there is 
an improvement in gaseous exchange. 
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4) Resolution – is the final phase; where macrophages  again predominate 
with the clearance of inflammatory response; neutrophil debris and 
bacteria. 
- The stages of evolution are classically seen in pneumococcal lobar 
pneumonia. 
- But in VAP the pattern is bronchopneumonia due to the mechanism 
of microaspiration. 
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Table 1 : RISK FACTORS FOR VAP(6) 
 
 
HOST RELATED:  
o Male sex 
o Underlying medical  condition 
o Immunosuppression 
o Chronic obstructive lung disease 
o Adult respiratory distress syndrome 
o Patient’s body position 
o Level of consciousness 
o Number of intubations 
o Medications 
o Admission for trauma 
 
DEVICE RELATED: 
o Endotracheal tube 
o Ventilator circuit 
o Nasogastric or orogastric tubes 
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PERSONNEL RELATED 
o Improper hand washing 
o Failure to change gloves between contact with patient 
o Not wearing personal protective equipment when antibiotic 
resistant bacteria have been identified. 
 
 
 
Microbiology: 
 The organism that causes VAP depends on the duration of mechanical 
ventilation. 
 
Table 2 : Organisms associated with VAP(7) 
 
 
EARLY ONSET : 
o Staphylococcus aureus 
o Streptococcus pneumoniae 
o Hemophilus influenzae 
o Proteus species 
o Serratia marcescens 
o Klebsiella pneumoniae 
o Escherichia coli 
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LATE ONSET : 
o Pseudomonas aeruginosa 
o Methicillin resistant staphylococcus aureus (MRSA) 
o Acinetobacter species 
o Enterobacter species 
 
 
- Early onset VAP is due to pathogens sensitive to antibiotics whereas 
late onset VAP is due to multi drug resistant and more difficult to 
treat bacteria. 
- VAP can also occur due to polymicrobial infection. 
- The prevalence of MDR organisms in VAP causation varies between 
institutions and also within the same institution.(8)  
- The risk factors for MDR organisms include: 
i) Hospital admission for > 2 days in the past 90 days. 
ii) Patients on chemotherapy or antibiotic therapy in the 
past 30 days. 
iii) Patients on hemodialysis. 
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- The commensals in oropharynx like Streptococcus viridans, coryne-
bacterium, coagulase negative staphylococcus and Neisseria species 
can also reach the lower airways in significant numbers. 
- VAP due to fungi and viruses have a very low incidence in the 
immunocompetent host. 
 
 Pathogens involved in the causation of VAP, their frequency and their 
possible modes of drug resistance are as follows: 
 
1) Pseudomonas (24.4%) - reduced expression of outer membrane 
porin channel, acquiring plasmid – mediated metallo – beta 
lactamases, increased regulation of efflux pumps. 
 
2) Staphylococcus aureus (20.4% of which > 50% MRSA): It 
produces a pencillin – binding protein (PBP) which has decreased 
affinity for beta lactam antibiotics. PBP production is encoded by the 
mecA gene. 
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3) Enterobacteriaceae (14% - includes Klebsiella spp; E.coli; 
Proteus spp., Enterobacter spp., Serratia spp., Citrobacter spp.) 
There  is  plasmid mediated production of ESBLs; plasmid mediated 
AmpC – type enzyme. 
4) Streptococcus species (12.1%) 
5) Hemophilus species (9.8%) 
6) Acinetobacter species (7.9%) – by production of metallo enzymes 
or carbapenamases. 
7) Neisseria species (2.6%) 
8) Stenotrophomonas maltophilia (1.7%) 
9) Coagulase negative staphylococcus (1.4%) 
10) Others (4.7% - includes Corynebacterium, Moraxella, 
Enterococcus, fungi). 
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ORGANISMS IMPLICATED IN  CAUSATION  OF  VAP 
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Clinical Features: 
- Previously any pneumonia even if it occurred within the first 24 hours 
of admission was considered a VAP. 
 
- According to the new surveillance definition now a period of stability 
on a ventilator for atleast 48 hours must be present for considering a 
ventilator associated event.(9) 
 
- The three categories of ventilator associated event are: 
i) Ventilator associated condition (VAC) 
ii) Infection related ventilator associated complication (IVAC) 
iii) Possible or probable VAP 
 
- Risk for VAP is highest during the initial five days of mechanical 
ventilation and the average duration between intubation and VAP 
development is 3.3 days.(10) 
 
- The incidence of VAP is directly related to the duration of mechanical 
ventilation. 
 
- The risk drops to 2% per day  after 5 to 10 days of ventilation and 
then to 1% per day thereafter.(11) 
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- VAP equates to half of all cases of hospital acquired pneumonia 
(HAP).(12) 
 
- The clinical manifestations of VAP are similar to other forms of 
pneumonia like 
o Fever >38oC 
o Leukocytosis 
o Increase in respiratory secretions; changes in sputum 
characteristics. 
o Pulmonary  consolidation on physical examination 
o New or changing radiographic infiltrate 
o Tachypnea 
o Tachycardia 
o Worsening oxygenation 
o Increased minute ventilation 
o Detection of a causative agent on culturing lower respiratory 
tract samples. 
o VAP rate is defined as number of VAPs / 1000 ventilator days. 
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Risk factors for early deterioration in CAP: 
Multilobar infiltrates Hypoalbuminemia 
Severe hypoxemia  
(arterial saturation <90%) 
Neutropenia 
Severe acidosis (pH <7.30) Thrombocytopenia 
Mental confusion  Hyponatremia 
Severe tachypnea  
(>30 breaths / min) 
Hypoglycemia 
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Pitfalls in the diagnosis of VAP: 
- Fever and leukocytosis are highly non-specific and can occur due to 
any condition that causes release of cytokines. The alternative causes 
are antibiotic associated diarrhea, sinusitis, UTI, pancreatitis, drug 
fever. 
- Chest X-ray suspicious of VAP may also point to the differentials of 
pulmonary edema, pulmonary infarction, atelectasis or acute 
respiratory distress syndrome. 
- It is also proven that colonization of airway is common and presence 
of microbes in tracheal secretions in the absence of clinical findings 
do not point towards VAP.(13) 
- Further more the use of chest X rays as a criterion for the diagnosis of 
VAP has raised questions of reliability and reproducibility.(14) 
- The lack of a gold standard for diagnosis of VAP is the major culprit 
for poor outcome. 
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- The application of clinical criteria frequently resulted in 
overdiagnosis of VAP mainly because of three common findings: 
o Tracheal colonization with pathogenic microbes in patients 
with endotracheal intubation. 
o Alternative causes of radiographic infiltrate in patients on 
mechanical ventilation. 
o Other causes of fever in critically ill patients. 
 
Hence the differential diagnosis of VAP includes: 
o Atypical pulmonary edema 
o Pulmonary contusion 
o Alveolar hemorrhage 
o Hypersensitivity pneumonitis 
o Acute respiratory distress syndrome 
o Pulmonary embolism 
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In conditions mimicking pneumonia the diagnosis of VAP can be ruled out 
by accurate diagnostic techniques. 
- The diagnostic dilemma has thus lead to debate and controversy. 
- The clinical approach enhanced by principles learned from 
quantitative culture studies is valid according to recent IDSA / ATS 
guidelines for diagnosis of HAP / VAP. 
- The lack of specificity in clinical diagnosis has led to the betterment 
in diagnostic criteria. 
- The clinical pulmonary infection score (CPIS) was thus developed 
which includes clinical, physiological, microbiological and 
radiographic evidence to allow a numerical value to predict the 
presence or absence of VAP. 
- The CPIS score was originally developed by Pugin et al and others. 
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CPIS 
S. 
No. Criteria Score 
 
1) 
 
Fever (oC)  > 38.5 but < 38.9 
 > 39 or <36 
 
 
1 
2 
 
2) 
 
Leukocytosis <4000 or >11000/µL 
   Bands >50% 
 
 
1 
1(additional) 
 
3) 
 
Oxygenation (mmHg)  
PaO2 / FiO2 <250 / no ARDs 
 
 
 
2 
 
4) 
 
Chest radiograph – localized infiltrate  
Patchy / diffuse infiltrate  
Progression of infiltrate  (no ARDs / CHF) 
 
 
2 
1 
2 
 
5) 
 
Tracheal aspirate 
moderate / heavy growth 
same morphology on Gram’s stain 
 
 
1 
1 (additional) 
 
 
Maximum score – 12 
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 At the time of original diagnosis, progression of infiltrate is unknown 
and tracheal aspirate cultures are unavailable, so the initial maximal score is 
8-10. 
Scores vary between 0 and 12. 
Score > 6 shows good correlation with presence of VAP.(15) 
The sensitivity of CPIS is 93% and specificity is 100%. 
- Despite the popularity of CPIS there is still a debate on its validity. 
- The inter observer variation in CPIS calculation jeopardizes its use in 
clinical practice.(16) 
- The American Thoracic Society (ATS) and Infective Diseases Society 
of America (IDSA) guidelines suggests lower respiratory samples for 
culture and microbiology.(17) 
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The methods of obtaining respiratory samples are: 
1) Endotracheal aspirate – easiest method. 
2) Bronchoalveolar lavage (BAL) – requires bronchoscopic guidance. 
3) Mini – bronchoalveolar lavage (mini BAL) – blind technique without 
bronchoscopic guidance. 
4) Protected specimen brush. 
- The samples can be analyzed both quantitatively and qualitatively. 
- It was also found that there is no difference in mortality in the 
invasive versus non-invasive groups and in quantitative versus 
qualitative cultures or in antibiotic use.(18) 
- Once samples are collected they are sent for Gram stain, culture and 
sensitivity. 
- Gram stain helps to identify the type of organism and also whether 
the material is purulent or not. 
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- Purulence is defined as > 25 neutrophils and < 10 squamous epithelial 
cells per low power field.(19) 
- Culture results are reported as semi-quantitative and or quantitative 
values. The samples are inoculated in blood agar, Mac Conkey agar 
and chocolate agar.  
- Semi quantitative values obtained are considered positive when the 
agar growth is moderate (+++) or heavy (++++) while quantitative 
positivity is > 105 cfu/ml. 
- The exact speciation of the organism and their antibiotic susceptibility 
takes a few days , but provides invaluable information. 
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Treatment of VAP: 
- The antibiotic selection depends on the duration of mechanical 
ventilation. 
- Early onset VAP requires limited spectrum antibiotics whereas late 
onset VAP requires broad spectrum antibiotics. 
- An updated local antibiogram for each hospital and ICU based on the 
local bacteriological patterns and susceptibilities guide initial empiric 
therapy. 
- De-escalation of the empiric antibiotic regimen is essential for 
reducing emergence of resistance, whereas delay in the initiation of 
antibiotic therapy leads to excess mortality risk with VAP.(20) 
- The duration of treatment for early onset VAP is 8 days and is much 
longer for late onset VAP . For VAP due to MDR organisms it  is 
usually around 14 days.(21) 
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Table 3 : Comparison of recommended initial empiric therapy for 
ventilator associated pneumonia according to time of onset(22 ,23) 
 
Early onset VAP Late onset VAP 
Second or third generation 
cephalosporin: 
i) Ceftriaxone 2 gm daily 
ii) Cefuroxime 1.5gm TDS 
iii) Cefotaxime 2gm TDS 
or 
Fluoroquinolones: 
i) Levofloxacin 750mg daily 
ii) Moxifloxacin 400mg daily 
or 
Aminopencillin + B lactamase 
inhibitor: 
 
Ampicillin + Sulbactam 3gm TDS 
or 
Ertapenam 1gm daily 
Cephalosporin 
e.g. Cefepime 1-2gm TDS / 
Ceftazidime 2gm TDS 
or 
Carbapenam: 
Eg: Imipenam cilastin 500mg QID 
or 1gm TDS 
Meropenam 1gm TDS  
or 
B lactam / B-lactamase inhibitor 
Eg. Piperacillin + tazobactam 4.5gm 
QID 
 
Plus Aminoglycoside: 
Amikacin 20mg /kg/day 
Gentamycin 7mg/kg/day 
Tobramycin  7mg/kg/day 
  
33 
 
Early onset VAP Late onset VAP 
or 
Antipseudomonal fluoroquinolone 
 
Ciprofloxacin 400mg TDS / 
Levofloxacin 750mg OD 
Plus 
Coverage for MRSA 
Vancomycin 15mg/kg BD 
or 
Linezolid  600mg BD 
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Table 4 : Recommended therapy for suspected or confirmed MDR 
organisms and fungal VAP (22, 23, 24) 
Pathogen Treatment 
 
MRSA 
Pseudomonas aeruginosa 
Acinetobacter species 
 
 
 
 
 
 
 
ESBL positive Enterobacteriaceae 
 
 
 
 
 
 
Carbapenams 
Eg : Imipenam + Cilastin 1gm TDS 
Meropenam 1gm TDS 
Or 
B lactam / B lactamase inhibitor  
Ampicillin + Sulbactam 3 gm TDS 
Or 
Tigecycline 100 mg loading dose 
then 50 mg BD. 
 
Carbapenam 
Imipenam + Cilastin 1 gm TDS 
Meropenam 1 gm   TDS 
 
 
 
  
35 
 
Pathogen Treatment 
 
Fungi 
 
 
 
 
Legionella 
 
Fluconazole 800mg  BD 
Caspofungin 70mg loading dose then 
50mg daily  or  Voriconazole  
4mg/kg/day 
 
Macrolides (eg : Azithromycin) 
or 
Fluoroquinolones (eg.Levofloxacin) 
 
 
 
 If the CPIS decreases over the first 3 days, antibiotics should be 
stopped after 8 days. An 8 day course is as effective as a 2 week course and 
is associated with less frequent emergence of antibiotic – resistant strains. 
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Prevention of VAP: 
- Prevention is better than cure is more applicable to VAP since it is a 
preventable disease and a proper approach reduces the duration of 
hospitalization, cost, morbidity and mortality. 
- There are multiple proven measures for the prevention of VAP. 
1) Since the presence of endotracheal tube is a significant risk factor for 
development of VAP the most important preventive measure is to avoid 
endotracheal intubation or minimize its duration. 
- Non invasive ventilation through a nasal or full face mask is an 
alternative to endotracheal intubation when possible. 
2) Nurses – play an important role as first line of defense in preventing 
bacterial colonization of the oropharynx and  gastrointestinal tract. 
- Proper hand washing for 10 seconds should be performed before and 
after contact with patients. 
  
  
37 
 
 
- Gloves should be worn while on contact with oral or endotracheal 
secretions. 
- Protective gowns are not recommended as a routine practice but they 
are useful when dealing with antibiotic resistant pathogens.(25) 
3) Oral decontamination by both mechanical and pharmacological methods 
reduce the number of bacteria within the patient’s oral cavity. 
- Mechanical interventions are brushing the tooth and rinsing of oral 
cavity to remove dental plaque.  
- Suctioning also removes dental plaque. 
- Pharmacological interventions involve use of antimicrobial agent like 
chlorhexidine oral rinse twice a day.(26) 
- It has been proven in a study that use of chlorhexidine decreased 
colonization and incidence of VAP in patients who underwent cardiac 
surgery. (27) 
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- There is no evidence based protocol for oral care and confirmed 
decrease in the incidence of VAP except for patients undergoing 
cardiac surgery. 
- VAP prevention can also be accomplished by the use of solution 
containing gentamycin, colistin and vancomycin every 6 hours.(28) 
4) Patients on mechanical ventilation for more than 48 hours are at a 16-
fold increased risk for gastro intestinal bleeding.(29) 
- Almost all patients receiving mechanical ventilation are given stress 
ulcer prophylaxis which increase gastric pH. 
- Pathogens multiply in the alkaline gastric environment and bacterial 
colonization of the stomach can lead to aspiration and colonization of 
the respiratory tract.(30) 
- Ranitidine an H2 receptor blocker significantly reduced the risk of 
bleeding without increasing the risk of VAP or mortality.(31) 
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- VAP rates did not differ between patients receiving ranitidine, 
omeprazole or sucralfate for stress ulcer prophylaxis.(32) 
- Stress ulcer prophylaxis does not play a pivotal role in the 
development of VAP but prevents serious gastro intestinal bleeding 
according the studies done so far. 
5) Mucus can become stagnant in the airways and become a medium for 
bacterial growth. 
- Endotracheal suctioning is mandatory while on mechanical 
ventilation to prevent contamination of airways. 
- There is no difference between the incidence of VAP with open 
versus closed suction systems.(33) 
- The suction catheter should be rinsed free of secretions away from the 
patient whenever a closed system is used. 
- Saline lavage has also been used to liquefy secretions and prevent 
mucus plugs in endotracheal tubes. 
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- But saline lavage of endotracheal tubes before suctioning dislodges 
pathogens into the lower airways thus increasing the risk of VAP.(34) 
- And also saline instillation did not liquefy secretions, instead it 
reduced the amount of oxygen reaching the lungs and lead to raised 
blood pressure, heart rate, intracranial pressure and risk of VAP.(35) 
- Thus the strategies used for eliminating the need for saline lavage are 
adequate hydration, proper humidification of the ventilator circuit and 
use of nebulizer or mucolytic agents. 
- Systemic antibiotic prophylaxis did not significantly reduce the 
incidence of VAP.(36) 
6) Turning of patients every 2 hours increases pulmonary drainage and 
reduces the development of VAP. 
- Using beds capable of continuous lateral rotation reduced the 
incidence of pneumonia but not mortality or duration of mechanical 
ventilation. So these beds are not routinely used for prevention of 
VAP.(37) 
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- But speciality  beds which are cost effective can be used in patients 
with poor oxygenation or with impaired wound healing. 
7) Colonization of ventilator circuit plays an important role in the 
development of VAP. 
- Changing the ventilator circuit daily does not reduce the incidence of 
VAP.(38) 
- The Centre for Disease Control and prevention does not suggest 
changing the ventilator circuit more than once every 48 hours and it is 
clearly indicated that changing the ventilator circuit as infrequently as 
once a week does not raise the risk for VAP.(39) 
- It is sufficient if the ventilator circuit is changed only when visibly 
soiled. 
- The comparison between heat and moisture exchangers on the 
incidence of VAP and also the form of humidity associated with 
increased incidence of VAP is inconclusive. 
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8) The presence of endotracheal tube is the main culprit for VAP 
development. So patients should be assessed on a daily basis for 
potential weaning and early extubation. 
- The methods used for assessing readiness for extubation include  
T-piece trials, weaning intermittent mandatory ventilation and 
pressure support ventilation.(40) 
9) Positioning of patients in a semirecumbent position with elevation of 
head end by 30o to 45o prevents gastric reflux and aspiration into the 
airways. 
- Simple elevation of the head end of bed by 30o reduces VAP by 
34%.(41) 
10) Also minimizing usage of narcotic agents prevents aspiration of gastric 
contents.(42) 
- Cautious reduction in the use of narcotics and sedatives must be done 
as pain limits deep breathing and impairs oxygenation. 
 
  
43 
 
 
- Daily interruption of continuous sedative infusions reduces the duration 
of mechanical ventilation by more than 2 days and duration of ICU stay 
by 3.5 days.(43) 
11) Gastric overdistension can be avoided by monitoring gastric residual 
volumes and administration of agents that enhance gastric motility as a 
measure to prevent VAP.(44) 
12) Oropharynx should be thoroughly suctioned while on endotracheal 
intubation as there is pooling of secretions above the cuffs of 
endotracheal tubes. 
- Maintaining adequate cuff pressure is necessary to prevent leakage of 
secretions and aspiration. 
- Pressure in the cuff should be maintained at no less than 20cm H2O 
(45)  and using tubes with ports for continuous suctioning reduces the 
incidence of VAP by 50%.(46) 
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13) There are ongoing studies being conducted on endotracheal tubes 
coated with silver nitrate to reduce the incidence of VAP. 
- Silver nitrate prevents formation of biofilm by interfering with the 
ability of bacteria to line the endotracheal tube.(47) 
14) Employment of outcome managers can be done to provide a 
comprehensive approach to VAP prevention.  
 A study has proved reduction in the duration of mechanical ventilation, 
hospital stay and mortality by employing an outcome manager.(48) 
15) The effects of VAP on the morbidity, mortality, duration of hospital 
stay and cost are immense. So education plays an important role in the 
management of VAP. 
- Using self study education modules on the nursing care of patients 
prone for VAP reduces the rate of pneumonia, duration of mechanical 
ventilation and cost of the disease.(49) 
Thus VAP rates in ICU can be reduced by utilizing a VAP bundle approach. 
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Measures for  preventing VAP(50, 51, 52) 
ICU focussed measures Institution focussed measures 
 
- Alcohol based hand washing 
- Discontinuation of invasive 
devices at the earliest. 
- Reduction of re-intubation 
rates. 
- Using oropharyngeal rather 
than nasopharyngeal feeding 
tubes. 
- Semi recumbent position of 
the patient (30-45o) 
- Maintaining endotracheal cuff 
pressure at 20cm H2O 
- Early initiation of 
tracheostomy. 
- Small bowel feeding rather 
than gastric feeding. 
- Use of probiotics. 
 
- Program for profiling of 
pathogens and creating 
antibiogram. 
- Avoid using of unnecessary 
antibiotics. 
- Using non-invasive positive 
pressure ventilation whenever 
feasible. 
- Use of antibiotic or silver 
coated ETT. 
- Oral decontamination policies. 
- Selective digestive 
decontamination (SDD) 
- Daily withholding of sedation 
- Early weaning and extubation 
protocols. 
- Removal of biofilm 
mechanically by mucus 
shaver. 
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Complications of VAP : (53) 
- Death is an important complication 
- Prolongation of mechanical ventilation and increase in the duration of 
ICU and hospital stay. This accounts for an additional expense. 
- Necrotising pneumonia particularly the one caused by Pseudomonas 
aeruginosa causes significant pulmonary hemorrhage. 
- These necrotizing infections lead to bronchiectasis and pulmonary 
scarring in the long run leading to recurrent episodes of pneumonia. 
- Pneumonias lead to a catabolic state in an already nutritionally 
compromised patient. 
- The muscle loss and general debilitation following VAP warrants 
prolonged rehabilitation and inability of independent functioning and 
need for nursing care. 
 
Follow up in VAP : (53) 
- Clinical improvement occurs in 48-72 hours following antibiotic 
initiation. 
- Patients are subjected to serial chest radiograph daily until being  
weaned off mechanical ventilation. 
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Prognosis : (53) 
- There is a significant association between VAP and mortality. 
- The crude mortality rate is 50-70% but the important issue is 
attributable mortality. 
- Many patients with VAP have underlying co-morbid conditions that 
would otherwise lead to death even if VAP did not occur. 
- Attributable mortality was previously more than 25% but now the 
rates are much lower. 
- The variability in the VAP mortality rates is related to the type of 
patient and the type of ICU. 
- VAP in trauma patients is not related to attributable mortality because 
the patients were otherwise previously healthy. 
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- The causative pathogen is the single most important factor in 
determining the outcome of VAP. MDR pathogens are associated 
with greater attributable morality than non-MDR pathogens. 
- Pneumonia due to Stenotrophomonas maltophilia is an indicator that 
patient’s immune system is compromised and death is almost 
inevitable. 
  
Materials & Methods 
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MATERIALS AND METHODS 
 
 An observational study was conducted in the Intensive Medical Care 
and Toxicology unit of RGGGH in association with the department of 
Microbiology for a period of six months from March 2017 to August 2017. 
Patients above 18 years of age who were on mechanical ventilation for more 
than 48 hours irrespective of etiology were included in our study . A total of 
50 patients were studied. Modified Clinical Pulmonary Infection Score was 
used to clinically diagnose VAP. Detailed history including the name, age  
sex ,underlying clinical condition ,date of admission  to the ICU, treatment 
being administered and clinical outcome of each patient was noted . Any 
lower respiratory tract infection that developed after 48 hours of mechanical 
ventilation and was judged not to have been incubating before mechanical 
ventilation was taken as VAP. The diagnosis of VAP was based on clinical 
and microbiological criteria. A clinical suspicion of VAP was made in 
patients with modified CPIS score ≥ 6. The diagnosis was confirmed when 
significant growth was obtained in the culture sample. 
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 Endotracheal aspirate (ETA) sample was collected from all patients 
admitted in the ICU requiring mechanical ventilation for more than 48 
hours. Patients who were already on mechanical ventilation before 
admission to the ICU and patients who had pneumonia on admission were 
excluded. Grams stain preparation and culture of all ETA samples were 
done. 
 
STATISTICAL ANALYSIS : 
 The statistical analysis was performed using standard tests . Pearson 
Chi Square Test was applied which revealed a significant p value of <0.05 .  
  
Observation & Results 
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OBSERVATION & RESULTS 
 
1)  INCIDENCE   OF   VAP: 32% 
 
 Frequency Percentage 
VAP 16 32.0 
No VAP 34 68.0 
Total 50 100.0 
 
 
   
 
 
 
16%
16%
68%
VAP  FOR  ALL 50 CASES
Early VAP
Late VAP
No VAP
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2)  AGE   WISE   DISTRIBUTION   OF   VAP: 
AGE GROUP Frequency Percent Valid Percent 
Cumulative 
Percent 
<30 23 46.0 46.0 46.0 
31-60 25 50.0 50.0 96.0 
ABOVE 60 2 4.0 4.0 100.0 
Total 50 100.0 100.0  
 
 
 
AGE WISE   DISTRIBUTION   AND   THEIR  OUTCOME  : 
 
OUTCOME 
AGE_GROUP 
Total 
<30 31-60 ABOVE 60 
Died 
Count 10 16 0 26 
% within OUTCOME 38.5% 61.5% 0.0% 100.0% 
Recovered 
Count 12 9 2 23 
% within OUTCOME 52.2% 39.1% 8.7% 100.0% 
Total 
Count 22 25 2 49 
% within OUTCOME 44.89% 51.02% 4.08% 100.0% 
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3)  SEX WISE   DISTRIBUTION   OF   PATIENTS: 
 
Sex Frequency Percent 
Female 18 36.0 
Male 32 64.0 
Total 50 100.0 
 
 
SEX WISE   FREQUENCY   OF   VAP: 
 
Sex Frequency Percent 
Female 5 31.3 
Male 11 68.8 
Total 16 100.0 
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OUTCOME 
 
SEX 
Total 
F M 
Died 
Count 9 17 26 
% within OUTCOME 34.6% 65.4% 100.0% 
Recovered 
Count 8 15 23 
% within OUTCOME 34.8% 65.2% 100.0% 
Total 
Count 17 32 49 
% within OUTCOME 34.69% 65.31% 100.0% 
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4)  EMERGENCY  AND  ELECTIVE  INTUBATION  AND  
 THEIR  CORRELATION  WITH  VAP: 
 
Method of  intubation Frequency Percent 
Elective 20 40.0 
Emergency 30 60.0 
Total 50 100.0 
 
 
 
VAP  IN  EMERGENCY  &  ELECTIVE  INTUBATION 
Method  of  intubation 
VAP SCORE 
Total 
NO VAP VAP 
Elective 
Count 15 5 20 
% within vap_score 44.1% 31.2% 40.0% 
Emergency 
Count 19 11 30 
% within vap_score 55.9% 68.8% 60.0% 
Total 
Count 34 16 50 
% within vap_score 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=0.751 p=0.386 
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5)  FREQUENCY  OF  EARLY  &  LATE  VAP: 
 
 Frequency Percent 
Early VAP 8 16.0 
Late VAP 8 16.0 
No VAP 34 68.0 
Total 50 100.0 
 
 
 Frequency Percent 
Early VAP 8 50.0 
Late VAP 8 50.0 
Total 16 100.0 
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50%50%
VAP  FOR  ALL 16 CASES
Early VAP Late VAP
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6)  CHEST XRAY  FINDINGS: 
 
 Frequency Percent 
Left (L)- (L) LL, (L) LZ 9 18.0 
Right(R) 9 18.0 
B/L LL 2 4.0 
N 30 60.0 
Total 50 100.0 
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7)   MICROBIOLOGICAL   PROFILE:  
 
NATURE  OF  TRACHEAL  ASPIRATE: 
 
TRACHEAL ASPIRATE Frequency Percent 
Non -Purulent 34 68.0 
Purulent 16 32.0 
Total 50 100.0 
 
GRAMS  STAIN Frequency Percent 
GNB 15 93.75 
GPC 1 6.25 
Total 16 100.0 
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GRAMS STAIN OF  CULTURED  ORGANISMS: 
 
 
 
 
94%
6%
GRAMS STAIN
GNB GPC
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ORGANISMS   GROWN   IN   CULTURE: 
 
Microbe  identified Frequency Percent 
Acinetobacter  spp. 8 50.0 
Cons 1 6.3 
Klebsiella  pneumoniae 4 25.0 
Pseudomonas aeruginosa 3 18.8 
Total 16 100.0 
 
 
 
 
  
50%
6%
25%
19%
CULTURE
Acineto bacter
cons
Klebsiella Pneumonia
Pseudomonas
aeruginosa
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GRAMS STAIN  &  CULTURE  RESULTS 
GRAMS  
STAIN 
CULTURE 
Total 
Acineto 
bacter Cons 
Klebsiella 
pneumoniae 
Pseudomonas 
aeruginosa 
GNB 
Count 8 0 4 3 15 
% 
within 
GRAMS 
STAIN 
53.3% 0.0% 26.7% 20.0% 100.0% 
GPC 
Count 0 1 0 0 1 
% 
within 
GRAMS 
STAIN 
0.0% 100.0% 0.0% 0.0% 100.0% 
Total 
Count 8 1 4 3 16 
% 
within 
GRAMS 
STAIN 
50.0% 6.2% 25.0% 18.8% 100.0% 
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8) CPIS SCORE &ITS SIGNIFICANCE   IN   DIAGNOSIS   OF  VAP: 
CPIS  SCORE NO VAP VAP Total 
Upto 6 
Count 34 5 39 
% within vap_score 100.0% 31.2% 78.0% 
Above 6 
Count 0 11 11 
% within vap_score 0.0% 68.8% 22.0% 
Total 
Count 34 16 50 
% within vap_score 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=29.968*p<0.001 
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9)  DURATION   OF   STAY   ON   MECHANICAL   VENTILATION   
FOLLOWING DEVELOPMENT   OF   VAP:  
 
Group Statistics  
DURATION  
OF 
VENTILATION 
N Mean Std. Deviation 
Std. 
Error 
Mean 
t value 
NO VAP 34 4.94 3.684 .632 5.368** 
VAP 16 15.06 9.692 2.423  
*p<0.001 
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10)  OUTCOME  IN  PATIENTS  FOLLOWING  DEVELOPMENT   
 OF  VAP: 
 
 
OUTCOME 
 
VAP SCORE 
Total 
NO VAP VAP 
Died 
Count 22 4 26 
% 64.71% 26.67% 53.06% 
Recovered 
Count 12 11 23 
% 35.29% 73.33% 46.94% 
Total 
Count 34 15 49 
% 100.00% 100.00% 100.00% 
 
 Pearson chi square =6.047**p=0.014 
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11)  RISK  FACTORS & UNDERLYING CO MORBIDITIES  
 OBSERVED IN  PATIENTS  ON  MECHANICAL   
 VENTILATION: 
 
 
 
 
  
 Frequency Percent Valid Percent 
Cumulative 
Percent 
No VAP 34 70.0 70.0 70.0 
DCLD 1 2.0 2.0 72.0 
DM 8 14.0 14.0 86.0 
MALIGNANCY 3 4.0 4.0 92.0 
MODS 1 2.0 2.0 94.0 
NO RISK  FACTOR 2 4.0 4.0 98.0 
STEROID 
THERAPY 1 2.0 2.0 100.0 
Total 50 100.0 100.0  
Discussion 
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DISCUSSION 
 
1)   INCIDENCE: 
 50 patients were   analysed   in   our  study.  34   patients   had   no  
VAP  and 16  patients developed  VAP.  The  overall  incidence  of  VAP  in  
RGGGH  according to this  study  is  32%.  The  prevalence  of  VAP  may  
vary  between 6  and 52  cases per  100  patients  depending  on  the  
population  studied.  In  an  ICU  on any  given  day  about  10%  of  
patients  will  develop  pneumonia,  VAP  in the  majority  of  cases. 
 
2)  AGE  DISTRIBUTION: 
 The  frequency  of  VAP  in this study  is  16  and  the  age  wise  
distribution  is  as  follows: 
 <30  years       - 11(68.8%) 
 31-60  years   - 5(31.3%) 
 
 The  higher  incidence  of  VAP  in  the age group  less  than  30  
years  can  be  attributed  to  more  number  of  patients  getting  admitted  
and  undergoing  mechanical  ventilation  in  this  age  group. 
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3)  SEX  DISTRIBUTION: 
 In  our  hospital  among  patients  who  developed  VAP  two thirds  
were  males (68.8%)  and  one  third  were  females (31.3%).  This  is  
because  of  increased  number  of male  patients  being  admitted. Also 
male gender as such is a risk factor for the development of VAP. 
 
4)  TYPES OF VAP: 
 Early  onset  VAP  is  pneumonia  which occurs  after 2  days  but  
within  4  days  of  mechanical  ventilation  whereas  late  onset  VAP  
occurs  4  days after  intubation.  Among  the  50  patients  studied  34(68%)  
had  no  VAP  and 16(32%)  had  VAP.  Among  those 16  who  developed  
VAP  8(16%)  had  early  VAP  and  8(16%)  had  late  VAP. The 
probability of getting VAP increases with the duration of mechanical 
ventilation. It  has been found that the risk for VAP increased from 5% in 
patients receiving one day of respiratory assistance to 68.8% in patients 
receiving more than 30 days. 
 
5)  ELECTIVE  VERSUS  EMERGENCY  INTUBATION: 
 In  our  study  30  patients  underwent emergency  intubation  and  20  
elective  intubation.  The  frequency  of  VAP  among  emergency  and  
elective  intubation  is  11  and  5  respectively.  The  method  of  intubation  
had  no  significant   association  with  the  development  of  VAP  
(p=0.386). 
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6)  CHEST  X  RAY  FINDINGS: 
Among  the  50  patients  studied  30  patients(60%)  had  a  normal  
chest  X ray.  9  patients  had  infiltration  in  the  left  lung , 9  
patients(18%)  had  right  lung  infiltrates.  Two(4%)  of them had bilateral  
infiltrates.  Previous  studies  have  shown  that  VAP  frequently  involves  
the  posterior  right  lower  lobe  and   more  so  because  of  aspiration  
being  the  most  common  precipitating  factor  for  VAP. Autopsy studies 
by Marquette C.H , M.C.Copin, F.Wallet, R.Neviere,  F.Saulnier, 
D.Mathieu, A.Durocher, P.Ramon and A.B.Tonnel 1995 have indicated that 
VAP frequently involves posterior right lower lobe. 
 
7)   MICROBIOLOGICAL  PROFILE: 
 Our study  showed  that  out  of  the  16  cases of  VAP,  15   were  
due  to  gram negative  organisms  and  one  was  due  to  gram  positive  
organism.  The  organisms  identified  in  culture  were  as  follows:   
 Acinetobacter species      - 50%  (8) 
 Klebsiella  pneumoniae                -  25%  (4) 
 Pseudomonas  aeruginosa     - 18.75%  (3) 
 Coagulase  negative  Staphylococcus  aureus(CONS) - 6.25%  (1). 
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 A previous study –nosocomial pneumonia in mechanically ventilated 
patients by Faisal Wahid, Naveed Masood, Asadullah Jafri showed the 
following profile of organisms- Pseudomonas aeruginosa(26%) , 
Staphylococcus aureus(20%) , Acinetobacter spp.(9%) , Proteus spp.(6%), 
Hemophilus spp.(6%) , Escherichia coli (6%), Klebsiella spp.(3%), 
Streptococcus pneumoniae(3%), Corynebacterium spp.(3%) & 
polymicrobial flora (9%). 
   This  study  reflects  the  higher  incidence  of  MDR  organisms  in the  
causation  of  VAP  in contrast   to  community  acquired  pneumonia  
where  Streptococcus  pneumonia  is  commonly  involved. 
 
8)   CPIS    AND  ITS  CORRELATION  WITH  VAP: 
The Clinical Pulmonary Infection Score(CPIS) includes clinical, 
microbiological and radiographic evidence to allow a numerical value to 
predict the presence or absence of VAP. Scores vary between 0 and 12 . 
CPIS  score  more  than  6  is  consistent  with  diagnosis  of  VAP.  In  our  
study  among  the  16  VAP  cases  11  had  a  score  more  than  6.  Thus  
CPIS  score  more  than  6  had  a  significant  association  with  the  
diagnosis  of  VAP  (p<0.001). 
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9)    DURATION  OF  MECHANICAL  VENTILATION   
       FOLLOWING  DEVELOPMENT  OF  VAP: 
         
 The risk for development of VAP is highest during the initial five 
days of mechanical ventilation and the average duration between intubation 
and VAP development is 3.3 days. The incidence of VAP is directly related 
to the duration of mechanical ventilation. The risk drops to 2% per day after 
5 to 10 days of mechanical ventilation  and then to 1% per day thereafter. 
        Among  the  16  cases  of  VAP  ,11  patients  were  on  mechanical  
ventilation  for  more  than  a  week  and  4  patients  less  than  a  week.  
There  is  a  significant  association  that  patients  had  to  be  on  
mechanical  ventilation  for  prolonged  periods  following  development  of  
VAP (p<0.001). 
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10)  OUTCOME  RELATED  TO  VAP: 
Among  the  16  cases  of  VAP: 
 4  -  died  (26.67%) 
 11-  recovered (73.33%) 
 1-patient  was  discharged  against  medical  advice  and hence  the  
outcome  was  unknown. 
 
 The  outcome  in  relation  to  VAP  had  a  significant  association  in  
our  study(p=0.0014).  Recovery  is  probably  attributed  to  better  nursing  
care  and  appropriate  antibiotic  coverage  for  adequate  period. 
  
Conclusion 
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CONCLUSION 
 
The  observations based  on  this  study  are: 
 VAP  occurs  frequently  and  is  associated  with  significant  
morbidity  in  critically  ill  patients. 
 The  incidence  of  VAP  is  directly  proportional  to  the  duration  of  
mechanical  ventilation. 
 Aspiration  is  a  major  precipitating  factor  for  developing  VAP  
and  diabetes mellitus poses  an  important  risk  factor  in  its  
causation. 
 There  is  a  high  incidence  of  MDR  organisms  in  patients  with  
VAP  unlike  in  community  acquired  pneumonia. 
 The  major  goals  of  VAP  management  are  early,  appropriate  
antibiotics  in  adequate  doses  followed  by  de-escalation  based  on  
microbiological  culture  results  and  clinical  response  of  the  
patient. 
 There  is  enough  evidence  to  indicate  that  VAP  is  preventable. 
  
Limitations of the study 
  
  
78 
 
 
 
LIMITATIONS OF THE STUDY 
 
 The drawback of the study is  the sample size.   Better results can be 
obtained if  a large group was studied and followed up for a quite 
long period.  
 
 Among the patients who died in this study mortality can be attributed 
to causes other than VAP. So  accurate mortality outcome rates  due 
to VAP cannot be measured. 
 
Bibliography 
  
BIBLIOGRAPHY 
1. Neelima Rajan, Uma Chaudary, VAP in tertiary care ICU – analysis of 
incidence, risk factors, mortality. 
2. Harrisons principles of Internal medicine. 
3. Morehead RS, Pinto SJ Ventilator associated pneumonia Arch Intern 
Med 2000 (Pub Med) 
4. Melsen WG, Rovers MM, Groenwold RH; Attributable mortality of VAP 
– a meta analysis of individual patient data from randomised prevention 
studies. 
5. Chastre J Fagon JY – Ventilator associated pneumonia. 
6. Table 1 – Beth Augustyn VAP – Risk factors and prevention. 
7. Table 2 – Beth Augustyn VAP – Risk factors and prevention. 
8. American Thoracic Society; Infectious diseases society of America (Pub 
Med). 
9. Annals ATS supplements. 
10. Rello J ollendoof D oster, Vera Llonch; Redman R; Kollef MH. VAP 
outcomes scientific Advisory Group. Epidemiology and outcomes of 
VAP in a large US database. Chest 2002; 122; 2115. 
11. Cook DJ; Walter SD; Cook RJ, Griffith LE; Guyatt GH. Incidence of and 
risk factors for VAP in critically ill patients. Ann Int Med 1998. 
12. Vincent JL; Bihari DJ; Wolff M, The prevalence of nosocomial infection 
in ICU in Europe (JAMA). 
13. Esteban A, Alia I, Tobin MJ; Benito S, Ibanez J. Modes of mechanical 
ventilation and weaning a national survey of Spanish hospitals. The 
Spanish lung failure collaborative group, Chest 1994. 
14. Wunder Ink RG, Wolden berg LS; Zeiss J, Day CM; Ciemins J. The 
radiologic diagnosis of autopsy proven ventilator associated pneumonia. 
Chest 1992. 
15. Pugin J; Auckenthaler R; Mili N Janssens OP; Lew PD; Suter PM. 
Diagnosis of VAP by bacteriologic analysis of bronchoscopic and non 
bronchoscopic blind bronchoalveolar lavage fluid. 
16. Zilberberg MD, Shorr AF. VAP the CPIS as a surrogate for diagnosis and 
outcome. Clin Infect. Disease 2010. 
17. ATS / IDSA – Guidelines for management of adult with HAP / VAP / 
HCAP. 
18. Berton DC, Kalil AC. Quantitative versus qualitative culture of 
respiratory secretions for clinical outcome in patients with ventilator 
associated pneumonia. 
19. Grgurich PE; Hudcova J, Lei Y, Craren DE, Sarwar A. Diagnosis of 
VAP: controversies and working toward a Gold Standard Curr Opin 
Infect Dis. 2013. 
20. Masterton RG – antibiotic de-escalation. Crit Care Clinic - 2011. 
21. Swoboda SM, Dixon T, Lipsett PA. Can the CPIS impact ICU antibiotic 
days? Surg Inf 2006. 
22. Torres A Ewigs; Lode H; Carlet. Defining, treating and preventing HAP. 
23. Dimopoulous G Poulakou, G Pneumatikos. Shoot-versus long duration 
antibiotic regimens for VAP – a systemic review & meta analysis. 
24. Walkey AJ, O Donell MR, Weiner RS, Linczolid vs glycopeptide 
antibiotics for the treatment of suspected MRSA nosocomial pneumonia 
a meta analysis of randomized controlled trials. Chest 2011. 
25. Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing 
HCAP 2003 recommendations of CDS and the health care infection 
control practices. Advisory Committee. 
26. Munro CL, Grap MJ. Oral Health and care in the ICU. State of the 
science. Am J Crit. Care 2004. 
27. De Riso AJ Jr. Ladowski JS, Dillon TA, Justice JN, Peterson AC. 
Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total 
nosocomial respiratory infection and non prophylactic systemic antibiotic 
use in patients undergoing heart surgery. Chest, 1996; 109. 1536-1961. 
28. Van Nieu Wenhoven CA, Buskens E, Bergmans DC, Vantiel DH, 
Ramsay G, Bonten MJ. Oral decontamination is cost saving in the 
prevention of VAP in ICU. Crit Care Med 2004. 
29. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastro intestinal 
bleeding in critically ill patients. Canadian critical care trials group N 
Engl J Med 1994. 
30. Donowitz LG, Page MC, Mileur BL, Guenther SH. Alteration of normal 
gastric flora in critical care patients receiving antacid and cimetidine 
therapy. Am J Infect Control, 1986. 
31. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and 
ranitidine for the prevention of upper gastrointestinal bleeding in patients 
requiring mechanical ventilation. Canadian critical care trials group. N 
Eng J Med. 1998. 
32. Yildiz Das D, Yapiciglu H, Yilmaz HL. Occurrence of VAP in 
mechanically ventilated paediatric ICU patients during stress ulcer 
prophylaxis with sucralfate, ranitidine and omeprazole. J Crit Care 2002. 
33. Zeitoun SS, de Barros AL, Diccini S. A prospective, randomized study of 
VAP in patients using a closed vs open suction system J Clin Nurs 2003. 
34. Moore J. suctioning techniques for the removal of respiratory secretions 
2003. 
35. Akgul S, Akyolcu N. Effects of normal saline on endotracheal suctioning. 
J Clin Nurs 2002. 
36. Leone M, Garcin F, Bouvenot J et al. VAP : breaking the vicious circle of 
antibiotic overuse. Crit Care Med. 2007. 
37. Kirschenbaum L, Azzi E, Sfier T, Tietjen P, Astiz M. Effect of 
continuous lateral rotation therapy on the prevalence of VAP in patients 
requiring long term ventilatory care. Crit Care Med 2002. 
38. Collard HR, Saint S, Matthay MA. Prevention of VAP an evidence based 
systematic review. Ann Intern Med 2003. 
39. Hess D. Ventilator Circuit change and VAP. 
40. Jubran A, Tobin MJ. Methods of discontinuing mechnical ventilation. 
41. AACN Practice Alert : VAP. AACN Clin Issues 2005. 
42. Kollef MH. The prevention of VAP. N Engl. J Med. 1999 
43. Kress JP, Pohlman As, O Connor MF, Hall JB. Daily interruption of 
sedative infusions in critically ill patients undergoing mechanical 
ventilation. N Eng J Med. 2000. 
44. Kollef MH. The prevention of VAP. N Engl J Med 1999 
45. Pfeifer LT, Orser L, Gefenc, Mc Guinness R, Hannon CV. Preventing 
VAP, what all nurses should know. Am J Nurs 2001. 
46. Craven DE. Preventing VAP in adults : Sowing seeds of change. Chest 
2006; 130; 251-260. 
47. Olson Mt., Harmon BG, Kollef MH. Silver coated endotracheal tubes 
associated with reduced bacterial burden in the lungs of mechanically 
ventilated dogs. Chest 2002; 121. 
48. Burns SM, Earven S, Fischer C, et al. Implementation of an institutional 
program to improve clinical and financial outcomes of mechanically 
ventilated patients. One year outcomes and lessons learned. Crit Care 
Med 2003. 
49. Zack OE, Garrison T, Trovillion E, et al. Effect of an education program 
aimed at reducing the occurrence of VAP. Crit care Med 2002. 
50. Anibiotic regimens for VAP – A systematic review and meta-analysis. 
Chest 2013. 
51. Swoboda SM, Dixon T, Lipsett PA. Can CPIS impact ICU antibiotic 
days? 
52. Valles J, Peredo R, Ferrer, Artigas A. Efficacy of single-dose antibiotic 
against early onset pneumonia in comatose patients who are ventilated. 
Chest 2013. 
53. Harrisons principles of Internal Medicine.  
  
Annexures 
 
ABBREVIATIONS 
VAP   - Ventilator Associated  Pneumonia 
BAL  -  Broncho Alveolar  Lavage 
CAP  - Community  Acquired  Pneumonia 
HAP  - Hospital Acquired Pneumonia 
COPD - Chronic  Obstructive  Pulmonary Disease 
MDR  - Multi Drug Resistant 
MRSA - Methicillin  Resistant  Staphylococcus  aureus 
UTI  - Urinary Tract  Infection 
ATS  - American Thoracic  Society 
IDSA  - Infectious  Diseases  Society  of  America 
CPIS  - Clinical  Pulmonary  Infection  Score 
FiO2  - Fraction  of  oxygen  in  inspired  air 
PaO2  - Partial pressure of  oxygen 
ETA  - Endotracheal Aspirate 
GNB  - Gram negative bacilli 
GPC  - Gram positive cocci 
CFU  - Colony forming unit 
ICU  - Intensive care unit 
IMCU - Intensive medical care unit 
RGGGH - Rajiv Gandhi Government General Hospital 
UZ  - upper zone 
LZ  - lower zone 
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 S. 
NO.
NAME AGE SEX DIAGNOSIS INDICATION
ELECTIVE / 
EMERGENCY
RISK 
FACTOR
CHEST X-
RAY
TEMP TLC
TRACHEAL 
ASPIRATE
GRAMS 
STAIN
CULTURE CPIS SCORE
EARLY / 
LATE VAP
ABG
DURATION OF 
VENTILATION
OUTCOME
1 Elango 30 M
Young stroke/ seizure 
disorder/ satus 
epilepticus
Status 
epilepticus
Emergency No
(R) UZ 
Haziness
102  ̊F 12700 Purulent GNB Acineto bacter 8 Late VAP
Met. 
Alkalosis
28 days Recovered
2 Madanlal 77 M
DM / SHT / myasthenia 
gravis
Resp. failure Elective DM N 100  ̊F 16600 Non Purulent No growth 3 No VAP
Resp. 
acidosis
8 days Recovered
3 Babu 43 M Unknown poisoning Resp. failure Emergency N N 10500 Non Purulent No growth 0 No VAP N 3 days Recovered
4 Chanakrishna 35 M
Toxic plant ingestion / 
hanging
Resp. failure Emergency
(R) 
Diffuse 
infiltrate
101  ̊F 21000 Purulent GNB
Kleibsella 
pneumoniae
7 Early VAP
Met. 
Alkalosis
14 days Died
5 Raj 32 M
Alcohol intoxication / 
self fall
Resp. failure Emergency N N 11000 Non Purulent No growth 0 No VAP N 3 days Recovered
6 Rohit Reddy 19 M
fulminant liver failure / 
ICH
Resp. failure Elective
(L) LZ 
Consolidat
ion
101  ̊F 14300 Non Purulent No growth 6 No VAP
Met. 
Alkalosis
3 days Died
7 Periyayee 40 F OPC Poisoning Resp. failure Elective
(R) LL 
Consolidat
ion 
99  ̊F 9100 Purulent GNB
Pseudomonas 
aeruginosa
6 Late VAP N 9 days Recovered
8 Devaki 24 F
Pre eclampsia / CVT/ 
P3L3
Resp. failure Emergency N 103  ̊F 15400 Purulent GNB Acineto bacter 6 Late VAP N 7 days Discharged AMA
9 Meena 20 F Neurotoxic snake bite Resp. failure Emergency N N 9400 Non Purulent No growth 0 No VAP N 3 days Died
10 Kumar 48 M OPC Poisoning Resp. failure Elective N 99  ̊F 15700 Non Purulent No growth 2 No VAP N 3 days Died
11 Sakunthala 65 F
DM/CAD / Alprax 
poisoning
Resp. failure Elective DM
(R) Pl. 
effusion
99  ̊F 12000 Non Purulent No growth 5 No VAP N 3 days Recovered
12 Nandhini 27 F Neurotoxic snake bite Resp. failure Emergency
(L) 
Diffuse 
infiltrate
99  ̊F 16800 Purulent GNB
Kleibsella 
pneumoniae
6 Early VAP N 11 days Recovered
13 Nandhini 44 F DM / Alprax poisoning Resp. failure Emergency DM
(R) LL 
infiltrate
100  ̊F 16900 Purulent GNB Acineto bacter 7 Early VAP N 4 days Recovered
14 Jegan 21 M
TB Meningitis / S/P VP 
Shunt
Poor GCS Elective
(R) UZ 
infiltrate
98.6  ̊F 16900 Purulent GNB Acineto bacter 6 Late VAP N 28 days Recovered
15 Kamatchi 30 F Crane killer poisoning Resp. failure Emergency
(R) LL 
Consolidat
ion 
102  ̊F 17300 Purulent GNB Acineto bacter 8 Early VAP N 5 days Recovered
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16 Thulasidoss 54 M OPC Poisoning Resp. failure Emergency
(L) LL 
Consolidat
ion
101  ̊F 110000 Purulent GNB
Klebsiella 
pneumoniae
7 Early VAP
Met. 
Acidosis
16 days Recovered
17 Mohan 42 M
Cannabis abuse / 
MODS / Sepsis
Resp. failure Elective MODS N N 16900 Non Purulent No growth 2 No VAP
Met. 
Acidosis
3 days Died
18
Muruganantha
m
24 M
Rat killer paste 
poisoning
GCS Elective N 100  ̊F 4700 Non Purulent No growth 0 No VAP
Met. 
Alkalosis
3 days Died
19 Nandhini 22 F
Fulminant hepatic 
failure
GCS Elective N 101  ̊F 8900 Non Purulent No growth 2 No VAP
Met. 
Alkalosis
2 days Died
20 Karunamoorthy 31 M Pyrethroid poisoning Resp. failure Elective N 104  ̊F 14600 Non Purulent No growth 4 No VAP
Met. 
Acidosis
2 days Died
21 Ramu 40 M Chlorpyrifos  poisoning Resp. failure Emergency N 99  ̊F 15400 Non Purulent No growth 3 No VAP N 4 days Recovered
22 Perumal 24 M
OPC Poisoning 
(Monocrotophos)
Poor GCS Elective
(L) LL 
Consolidat
ion
101  ̊F 15580 Purulent GNB
Pseudomonas 
aeruginosa
7 Late VAP N 17 days Recovered
23 Kayan 40 M
OPC - Dimethoate 
poisoning
Poor GCS Emergency N 100  ̊F 1060 Non Purulent No growth 0 No VAP N 4 days Recovered
24 Shankar 25 M Near drowning Poor GCS Emergency
B/L LL 
Haziness
101  ̊F 10000 Non Purulent No growth 5 No VAP ARDS 4 days Recovered
25 Bhavani 22 F Hanging Poor GCS Emergency
(L) LL 
Consolidat
ion
100  ̊F 15400 Non Purulent No growth 5 No VAP 10 days Recovered
26 Saravanan 52 M Hanging Poor GCS Emergency N N 11000 Non Purulent No growth 1 No VAP 2 days Recovered
27 Mariyammal 25 F Hanging Resp. failure Emergency N N 10600 Non Purulent No growth No VAP
Resp. 
alkalosis
3 days Recovered
28 Silambarasan 30 M
RHD/MS/Post DVR (L) 
ICH
Poor GCS Elective
(L) LL 
Consolidat
ion
100  ̊F 17700 Purulent GNB
Pseudomonas 
aeruginosa
7 Late VAP
Resp. 
alkalosis
32 Recovered
29 Dilli Rani 23 F Neurotoxic snake bite Resp. failure Emergency N 100  ̊F 21000 Non Purulent No growth 3 No VAP N 3 Recovered
30 Yuvaraj 20 M Hanging Poor GCS Elective
(L) LL 
Consolidat
ion
100  ̊F 16900 Purulent GNB Acineto bacter 7 Early VAP 11 Recovered
31 Elumalai 40 M OPC  poisoning/DM Resp. failure Emergency DM N 99  ̊F 10400 Non Purulent No growth 2 No VAP N 3 Recovered
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32 Malathi 26 F VT / Hypoglycemia cardiac arrest Emergency N 100  ̊F 11000 Non Purulent No growth 2 No VAP
Resp. 
alkalosis
4 Died
33 Valli 48 F
Retroperitoneal 
Sarcoma
Resp. failure Emergency
Malig 
nancy
N 102  ̊F 8900 Non Purulent No growth 2 No VAP N 7 Died
34 Kumar 48 M OPC poisoning Resp. failure Elective DM N 102  ̊F 11600 Non Purulent No growth 3 No VAP N 4 Died
35 Savithri 57 F DM / SHT/ CLL Resp. failure Emergency
DM / 
Malignanc
y
N 102  ̊F 55500 Non Purulent No growth 4 No VAP Met. acidosis 19 Died
36 Mahesh 38 M OPC Poisoning Resp. failure Elective N 102  ̊F 2700 Non Purulent No growth 2 No VAP Met. acidosis 15 Died
37 Rajasekhar 21 M OPC Poisoning Resp. failure Emergency N N 3500 Non Purulent No growth 0 No VAP
Resp. 
alkalosis
5 Died
38 Sripal 34 M DCLD/HE/Renal failure Poor GCS Elective DCLD N 100  ̊F 11000 Non Purulent No growth 2 No VAP Met alkalosis 5 Died
39 Ramya 20 F
Seizure disorder/ 
status epilepticus
Status 
epilepticus
Elective N 99  ̊F 8500 Non Purulent No growth 1 No VAP N 4 Died
40 Jancy Rani 21 F SLE / LN / ARDS ARDS Emergency
Steroid 
therapy
B/L LL 
Haziness
101  ̊F 19000 Non Purulent No growth 6 No VAP ARDS 5 Died
41 Simmadhri 25 M Carbamate poisoning Resp. failure Emergency No
(L) LZ 
Haziness
102  ̊F 14300 Purulent GNB Acineto bacter 8 Early VAP N 6 Recovered
42
Udaya 
Chandran
25 M
DM / DKA / Acute 
pancreatitis
Poor GCS Emergency DM
(R) LZ 
Haziness
100  ̊F 16700 Purulent GNB
Klebsiella 
pneumoniae
8 Early VAP Met. acidosis 4 Died
43 Abdul Jaleel 31 M
Acute meningo 
encephalitis
Poor GCS Elective N 100  ̊F 14200 Non Purulent No growth 3 No VAP 3 Died
44 Mohan 45 M
OPC Poisoning 
(monocrotophos)
Resp. failure Emergency N 98.6  ̊F 7300 Non Purulent No growth 0 No VAP 3 Died
45 Seenivasagam 50 M (L) ICH / DM Poor GCS Elective DM N 99  ̊F 4800 Non Purulent No growth 1 No VAP 3 Died
46 Elumalai 36 M
OPC(Quinalphos) 
poisoning
Resp. failure Emergency
(R) UZ 
Opacity
99  ̊F 11300 Purulent GPC CONS 6 Late VAP
Resp. 
alkalosis
20 Died
47 Ramamoorthi 43 M
GBS / autonomic 
dysfunction
Resp. failure Elective N 99  ̊F 3800 Non Purulent No growth 1 No VAP 5 Died
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48 Amarakavi 23 M
RTA / SDH / S/P 
Craniotomy
Resp. failure Emergency
(L) LL 
Haziness
101  ̊F 15900 Purulent GNB Acineto bacter 8 Late VAP
Met. 
Acidosis
29 Died
49 Selvi 31 F
Hypokalemia / 
Quadriparaesis
Resp. failure Emergency N 99  ̊F 25500 Non Purulent No growth 3 No VAP 9 Died
50 Sangeetha 43 F AML / SAH Resp. failure Emergency
Malig 
nancy
N 102  ̊F 6300 Non Purulent Growth 2 No VAP
Met. 
Acidosis
8 Died
